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1. Introduction 
Glaucoma is a neurodegenerative disease characterized by a progressive loss of retinal 
ganglion cells (RGCs), the output neurons of the retina. Elevated intraocular pressure (IOP) 
has long been recognized as a major risk factor for human glaucoma (Kass et al., 1980; 
Quigley et al., 1994; Tsai & Kanner, 2005). Indeed, in animal models of glaucoma, ranging 
from rodents (Johnson & Tomarev, 2010) to primates (Gaasterland & Kupfer, 1974; Hare et 
al., 2004), elevated IOP produced either biophysically (Gaasterland & Kupfer, 1974; 
WoldeMussie et al., 2001) or genetically (Anderson et al., 2001; Ju et al., 2009) can lead to 
RGC degeneration similar to that found in human glaucoma (Quigley, 2005). 
A common and effective treatment for glaucoma is the use of IOP lowering topical drugs 
that act at a variety of cellular targets, such as the α2 and β adrenergic receptors (Tsai & 
Kanner, 2005). However, in many patients, the disease continues to progress despite 
successful IOP reduction with topical drugs (Heijl et al., 2002; Vasudevan et al., 2011).  
Brimonidine, a selective α2 receptor agonist, is the active ingredient in one class of topical 
IOP lowering drugs, such as Alphagan® and Alphagn-P®. Brimonidine has been shown to 
protect RGCs in experimental glaucoma (WoldeMussie et al., 2001; Dong et al., 2008), retinal 
ischemia (Donello et al., 2001; Lai et al., 2002), optic nerve injury (Yoles et a., 1999), and 
retinal excitotoxicity (Dong et al., 2008). In experimental glaucoma, brimonidine’s 
neuroprotective effect appears to be independent of its IOP lowering action (Dong et al., 
2008; Hernandez et al., 2008). More recently, in a randomized, double-masked, multicenter 
clinical trial, brimonidine has been shown to be more effective in slowing disease 
progression (visual field loss), compared with timolol (a β blocker), despite the fact that the 
mean treated IOP was similar in both treatment groups at all time points (Krupin 2011). 
These clinical data suggest that brimonidine may have a direct RGC protective effect that is 
independent of its IOP lowering action in human low-pressure glaucoma, similar to that 
found in experimental glaucoma (Dong et al., 2008; Hernandez et al., 2008). 
In this chapter, we will summarize the results of our recent studies on the mechanisms that 
underlie brimonidine’s protection of RGCs in experimental glaucoma and retinal 
excitotoxicity. We will first describe the properties of RGCs and the ex vivo and in vivo 
models used in our studies on the mechanisms of RGC injury and protection. Then we will 
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discuss neuronal Ca++ signaling in health and disease, as well as the properties of the α2 
receptor and its intracellular signaling pathways responsible for brimonidine mediated 
neuroprotection. A particular emphasis will be placed on the role of the α2 receptor in 
modulation of retinal Ca++ signaling pre- and postsynaptic to RGCs. Finally, we will briefly 
discuss other beneficial effects of brimonidine in retinal disease models reported in the 
literature. 
2. Properties of RGCs 
The vertebrate retina is a part of the central nervous system (CNS) and RGCs are a type of 
CNS projection neuron (Dowling, 1987; Rodieck, 1973). Unlike all other types of retinal 
neurons that receive their synaptic inputs and send the outputs within the retina, RGCs 
receive synaptic input at the inner plexiform layer (IPL) of the retina, but transmit their 
output at locations far away from the retina via long axons (a major component of the optic 
nerve). Also unlike the majority of the retinal neurons, such as photoreceptors, bipolar  
cells, and horizontal cells, that use only graded potentials to transmit the visual signal, 
RGCs are the only retinal neurons that use exclusively action potentials (nerve spikes) to 
transmit signals to their postsynaptic neurons at higher brain centers, such as lateral 
geniculate nucleus and superior colliculus (Dowling, 1987; Ito et al., 2008; Rodieck & 
Watanabe, 1993).  
While these unique functional and structural properties of RGCs are required for long-range 
signaling as projection neurons, they also cause significantly elevated metabolic demand 
due to increased energy (ATP) usage to prevent intracellular ionic imbalance resulting from 
the high frequency spiking activity and for long-range bidirectional axonal transport. This 
elevated metabolic demand likely makes RGCs more susceptible to various stresses under 
pathophysiological conditions, such as intracellular Ca++ dysregulation (Dong et al., 2008), 
metabolic challenge caused by elevated IOP (Baltan et al., 2010) or vascular abnormality 
(Moore et al., 2008), and axonal ionic imbalance such as Na+ overload (Dong & Hare, 2005; 
Waxman et al., 1994).  
3. Ex vivo and in vivo models used in determination of the mechanisms of 
RGC injury and α2 protection 
In order to determine the mechanisms that underlie high IOP induced RGC degeneration in 
experimental glaucoma and protection by brimonidine, we used two ex vivo models: live rat 
retinal slice (Dong et al., 2007) and the isolated, flat-mount rat and rabbit retina (Dong et al., 
2008) and two in vivo models: a rat chronic ocular hypertensive glaucoma model 
(WoldeMussie et al., 2001; Dong et al., 2008) and a rabbit retinal excitotoxicity model (Dong 
et al., 2008). We use the ex vivo models to study intracellular signaling pathways of the α2 
receptor and its interactions with the voltage- and transmitter-gated Ca++ channels, namely 
the L-type Ca++ channel and the NMDA receptor. We use in vivo models to test our 
hypotheses based on our findings from the ex vivo models. Rodent ocular hypertensive 
models of various kinds have been widely used in glaucoma research (Johnson & Tomarev, 
2010). However, the other three models, namely the retinal slice, in situ RGCs in the isolated 
retina, and the rabbit retinal excitotoxicity model, are not commonly used. We therefore will 
briefly describe their unique features and utility in glaucoma research. 
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3.1 Live retinal slice 
Both the retinal slice and isolated flat-mount retina are ex vivo preparations that retain rather 
well natural intercellular neural connections/interactions and have neuronal gene express 
patterns that are very similar to those under in vivo conditions. And yet, they allow 
experimentation under more controlled conditions than possible under in vivo conditions. 
For example, the compositions of extracellular media can be controlled precisely and 
changed rapidly and retinal neurons can be accessed readily for electrophysiological 
recording and optical imaging/labeling while still maintaining connections with their 
neighboring neurons and other supporting cells such as glial cells. Therefore, these ex vivo 
preparations are particularly useful for studies aiming at understanding the mechanisms of 
eye diseases and drug action. 
 
 
Fig. 1. The live rat retinal slice preparation. See the text for details 
Intracellular Ca++ plays a critical role in neuronal signal processing and communication, 
such as neurotransmitter release from presynaptic axon terminals. It is also a key signaling 
molecule to trigger cell apoptosis/death under pathophysiological conditions (see the next 
section below). Figure 1A shows an acutely cut and superfused rat retinal slice in which the 
major retinal layers (nerve fiber layer, NFL; ganglion cell layer, GCL; inner plexiform layer, 
IPL; inner nuclear layer, INL; outer plexiform layer, OPL; outer nuclear layer, ONL; photo-
receptor inner segment, IS; photoreceptor outer segment, OS) are easily visible under the 
microscope with a water immersion objective. When retinal slices are loaded with a 
membrane permeable fluorescent Ca++ dye (Fluo-4 AM), changes in cytosolic free Ca++ 
under various experimental conditions can be recorded with a confocal imaging system (for 
technical details see Dong et al., 2007). Membrane depolarization induced by a 5-8 sec rapid 
perfusion of high K+ Ringer solution elicited a robust Ca++ signal (red traces in Fig. 1B) at 
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IPL where RGCs communicate with their presynaptic neurons, such as bipolar and 
amacrine cells. A representative area for the Ca++ measurement at IPL is indicated by the 
white rectangle in Fig. 1A. The high K+ induced Ca++ signals were abolished completely 
after perfusing with either a Ca++-free Ringer solution or normal Ringer solution that 
contained 100 μM Cd++, a broad-spectrum Ca++ channel blocker (green traces in Fig. 1B). 
This indicates that the signal is generated by Ca++ influx through depolarization activated 
Ca++ channels at IPL. 
The Ca++ influx into bipolar cell synaptic terminals (located at IPL) is likely a major 
contributor to the depolarization induced Ca++ signal shown in Fig. 1B. Bipolar cells are key 
presynaptic partners of RGCs. Bipolar cells release glutamate (Matsui et al., 1998) as their 
neurotransmitter at the synaptic terminals to communicate with RGCs and amacrine cells 
and Ca++ influx is needed to trigger the release. Therefore, it is not surprising that voltage-
gated Ca++ channels are highly concentrated at bipolar cell terminals for glutamate release 
(Pan, 2000, 2001). When these Ca++ channels are over activated under pathophysiological 
conditions, such as retinal ischemia, glutamate released from bipolar terminals could be a 
major contributor to the significantly elevated extracellular glutamate that can cause 
excessive activation of the NMDA receptor on RGCs and lead to RGC dysfunction/death.  
The right panel of Fig. 1C shows the confocal image of a Ca++ dye labeled bipolar cell from a 
live rat retinal slice. The major parts of the cell, the dendrites, soma, axon, and synaptic 
terminals (indicated by the green oval), are clearly visible. The Ca++ dye (a cell membrane-
impermeable version of Fluo-4) was delivered to the bipolar cells intracellularly via a patch-
clamp electrode (not shown). Membrane depolarization induced by a 0.5 sec voltage step 
from the holding potential of -70 mV to -10 mV through the recording electrode elicited at 
the bipolar cell terminals a large cytosolic free Ca++ signal (Fig. 1D, arbitrary units) that was 
completely eliminated by removing Ca++ from the Ringer solution. Ca++ channels in the 
CNS, particularly those at presynaptic terminals, are important drug targets and in situ 
bipolar terminals provide an excellent ex vivo system for the studies on neuromodulation of 
presynaptic Ca++ channel activity by brimonidine and other neuroactive drugs/drug 
candidates.  
3.2 In situ RGCs in the isolated flat-mount retina 
Because of the selective vulnerability of RGCs in glaucoma, a detailed characterization of 
physiological and pharmacological properties of RGCs can help to understand the 
mechanism of RGC injury in glaucoma and the mechanism of action of neuroprotective 
drugs, such as brimonidine, as well as to identify novel drug targets for the treatment of 
glaucoma. In situ RGCs in the acutely isolated, superfused retina (Fig. 2) offer a unique 
opportunity to study the pharmacological properties and intracellular signaling pathways of 
various neural active drugs and drug candidates on RGCs without significantly altering 
retinal synaptic connections and RGC gene expression pattern compared to RGC cell lines or 
even primary cultures.   
Fig. 2A shows a bright field image of a piece of live isolated, superfused rabbit retina 
viewing from the vitreous side. The axon bundles (the main component of the nerve fiber 
layer) of RGCs are visible. After the inner limiting membrane and nerve fiber layer were 
carefully poked through and the debris were removed with a cleaning glass micropipette, 
somas of in situ RGCs were revealed and whole-cell recordings could be performed with 
patch-clamp electrodes (Fig. 2B). We routinely include a membrane-impermeable Ca++ dye 
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in the patch electrodes. Therefore, neurotransmitter agonist (such as NMDA) induced 
transmembrane currents and cytosolic free Ca++ signals can be measured simultaneously. 
Fig. 2C shows the NMDA (applied with the co-agonist glycine) induced inward current and 
Ca++ signal from an in situ RGC. A transient light response from that RGC is also visible 
immediately after the onset of the excitation light for Ca++ imaging. After electro-
physiological and optical recordings, the identity of the recorded cell can be confirmed with 
confocal imaging (Fig. 2D). 
 
 
Fig. 2. In situ RGCs in the isolated, superfused rabbit retina. See the text for details 
3.3 Rabbit retinal excitotoxicity model 
Excessive activation of glutamate receptors, particularly the NMDA receptor, has been 
suggested as a key factor that contributes to high IOP induced RGC loss in experimental 
glaucoma, regardless how IOP is elevated and what animal species is selected (Dong et al., 
2008; Hare et al., 2004; Ju et al., 2009; WoldeMussie et al., 2002).  
Intravitreal injection of NMDA, a selective agonist of the NMDA sub-type of ionotropic 
glutamate receptor, can also induced RGC loss by directly activating the NMDA receptor on 
RGCs. The rat (Siliprandi et al., 1992) and mouse (Ito et al., 2008) retinal NMDA models 
have been used in glaucoma research to explore the mechanism of RGC injury and to 
evaluate efficacy of potential RGC protective drug candidates. However, relatively hard to 
perform intravitreal injection and lack of macular-like structure are two major 
disadvantages of the rodent models.  
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We therefore developed a rabbit retinal NMDA model (Fig. 3, see also Dong et al., 2008). 
The rabbit has large eyes and it’s significantly easier to conduct multiple intravitreal 
injections in rabbit eyes with low risk of causing accidental retinal or lens damage (both of 
which can affect RGC survival directly or indirectly). This facilitates in vivo studies on the 
mechanisms of RGC protection by brimonidine or other novel neuroprotective agents.  
 
 
Fig. 3. The rabbit model to evaluate NMDA excitotoxicity. See the text for details 
The rabbit retina also has a visual streak that is an elongated macular-like structure that has 
the highest density of neurons in the retina (Fig. 3C and 3D). This allows us to study the 
differential vulnerability of RGCs located at the center (visual streak) versus more peripheral 
retinal locations, which may provide an important clue as to why the central visual fields 
are more resistant to glaucomatous injury in human glaucoma (Dong et al., 2011). Fig. 3A 
shows an isolated rabbit retina. We routinely cut out a circular piece (8 mm in diameter) 
from the central retina using the optic nerve head as a marker to ensure that we compare the 
same regions of the retina between different experimental groups. We count the neurons in 
the ganglion cell layer at 25 locations in a 5x5 array using a computer-controlled automated 
microscope stage (see Dong et al., 2008 for technical details). The circular piece of the retina 
is aligned carefully so that the first row of 5 sites is located within the visual streak (Fig. 1A). 
Fig. 1B shows a representative cross section of H&E stained rabbit retina. The individual 
dots in Fig. 1C are nuclei of RGCs and displaced amacrine cells in the ganglion cell layer 
labelled with a fluorescent nuclear dye (DAPI). The density of the neurons drops rapidly 
from the visual streak (row 1) to more peripheral retina (rows 2 to 5). Fig. 1D shows the 3D 
plot of the cell density profile based on neuron density of these 25 sites.  
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4. Intracellular Ca++ dysregulation and neurodegeneration 
There is compelling evidence that intracellular Ca++ dysregulation is a key contributor to 
neurodegeneration in a wide range of CNS degenerative diseases, such as Alzheimer’s 
disease and Parkinson’s disease (Bezprozvanny, 2009). In addition to age and genetically 
related changes in intracellular Ca++ handling, Ca++ overload as a result of excessive 
activation of voltage- and ligand-gated Ca++ channels on the neuronal cell membrane, 
particularly the NMDA receptor, plays a central role in intracellular Ca++ dysregulation 
(Choi, 1985; Choi et al., 1988). The NMDA receptor is a type of ionotropic glutamate receptor 
that is coupled to a cation channel which has a high Ca++ permeability (MacDermott et al., 
1986; Sattler & Tymianski, 2001). It is therefore sometimes called the ligand-gated Ca++ 
channel. Unlike the other types of ionotropic glutamate receptors (such as AMPA and 
kainate receptors) that desensitize rapidly and significantly in the continuous presence of 
the agonist (Hestrin et al., 1990; Lukasiewicz et al., 1995), the NMDA receptor shows 
significantly less desensitization in the continuous presence of the agonists (MacDermott et 
al., 1986; Matsui et al., 1998) and is therefore particularly effective in causing intracellular 
Ca++ overload when excessively activated. 
Intracellular Ca++ overload can trigger neuronal apoptosis via a number of cross-amplifying 
pathways, including Ca++-activated proteases and their downstream effectors such as 
calpain and calpain-activated caspases (Das et al., 2005; Sharma & Rohrer, 2004), 
mitochondrial dysfunction and damage directly produced by Ca++ overload (Starkov et al., 
2004), and Ca++ dependent cytosolic overproduction of free radicals (Brennan et al., 2009; 
Sattler et al., 1999). 
4.1 NMDA receptor, intracellular Ca++ dysregulation, and RGC degeneration  
Intracellular Ca++ dysregulation/overload caused by deregulated retinal glutamatergic 
transmission is also likely a key mechanism that causes RGC dysfunction (Hare & Wheeler, 
2009) and degeneration in disease states, such as acute retinal ischemia (Lagreze et al., 1998) 
and experimental glaucoma (Dong et al., 2008; Harada et al., 2007; Ju et al., 2009). For 
example, vulnerability of RGCs in acute retinal ischemia is associated not only with NMDA 
receptor activity (Lagreze et al., 1998), but also with significantly elevated vitreal glutamate 
level (Donello et al., 2001; Lagreze et al., 1998). Brimonidine not only protects RGCs in 
retinal ischemia, but also significantly reduced vitreal glutamate concentration (Donello et 
al., 2001), suggesting that it either prevents excessive release of glutamate or enhances its 
uptake, or both. 
5. The α2 adrenergic receptor 
The α2 adrenergic receptor is a G-protein coupled receptor (GPCRs, Fig. 4) that can signal 
through both Gα and Gβγ subunits (Delaney et al., 2007; Maze, 1991). In the CNS, the major 
functional role of the α2 receptor is modulation of neurotransmitter release (Starke, 2001). 
This action is through the classical presynaptic inhibition either by inhibiting Ca++ channels 
(Boehm, 1999; Starke, 2001), activating K+ channels (Bünemann et al., 2001), or reducing 
active release sites (Delaney et al., 2007). Presynaptic inhibition by the α2 receptor in the 
brain is mediated by the Gβγ subunits (Fig. 4B, see also Delaney et al., 2007). 
The α2 receptor is coupled to Gαi/o (i for inhibition of adenylate cyclase and o for olfactory 
type). When signaling through the Gα subunit, α2 receptor activation leads to inhibition of 
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adenylate cyclase, resulting in a reduction of cAMP production. cAMP is an important 
intracellular second messenger that modulates many aspects of cellular function through 
interacting with various downstream effectors (Maze, 1991), such as protein kinase A. Alpha 2 
receptors are known to be expressed in retinal neurons, including retinal bipolar cells (Dong 
et al., unpublished results) and RGCs (Kalapesi et al., 2005). 
5.1 Suppression of NMDA receptor function by brimonidine 
As shown in Fig. 2, robust NMDA induced transmembrane currents and cytosolic free Ca++ 
signals can be recorded from in situ RGCs in the isolated, superfused retina when they are 
voltage-clamped close to their resting membrane potential at -70 mV. We reported (Dong et 
al., 2008) that pretreatment with brimonidine produced a significant suppression of both of 
these NMDA induced signals in RGCs (Fig. 5B and 5C). NMDA (plus glycine) was applied 
with a local perfusion micropipette (Fig. 5A) that was connected to a computer-controlled, 
multi-channel drug delivery system in a 0 Mg++ Ringer. This allowed rapid delivery and 
removal of NMDA as well as effective activation of the NMDA receptor without the 
voltage-dependent Mg++ block. Brimonidine and atipamezole (a selective α2 antagonist) 
were delivered using both bath (the whole-chamber) and the local perfusion systems. The 
Ca++ dye and some tool compounds, such as GDP-βS, were delivered intracellularly to the 
RGC using the recording pipette.  
The suppressive effect of brimonidine on NMDA responses is mediated by the α2 receptor, 
because this effect was completely blocked (Fig. 5C) by a highly selective α2 antagonist, 
atipamezole (Virtanen, 1989). Brimonidine’s effect is direct on RGCs since it was also 
completely blocked (Fig. 5C) by intracellularly applied GDP-βS, a membrane impermeable 
GPCR inhibitor that blocks exchange of GDP for GTP on the Gα subunit of the G-protein 
(Fig. 4A), an obligate event required for α2 receptor activation. Other intracellularly 
delivered tool compounds that act at various sites along the α2 receptor signaling pathway 
also blocked brimonidine’s effect on NMDA receptor function (see section 5.2),  
confirming that brimonidine’s effect is direct on RGCs, not an indirect effect through other 
retinal cells. 
5.2 Brimonidine suppresses NMDA receptor function through the Gαi pathway  
Using tool compounds acting at different sites along the Gαi signaling pathway (Fig. 4), we 
have obtained compelling evidence that brimonidine’s effect on NMDA receptor function is 
mediated almost exclusively by the Gαi pathway (Dong et al., 2008). We found that SQ22536, 
a selective inhibitor of adenylate cyclase (Fabbri et al., 1991), mimicked the effect of 
brimonidine on NMDA receptor function (Fig. 6A). On the other hand, forskolin 
(abbreviated as “forsk” in Fig. 6B), an activator of AC (de Souza et al., 1983), blocked the 
effect of brimonidine (abbreviated as “brimo” in Fig. 6B). This suggests that intracellular 
cAMP is an important regulator of NMDA receptor function in RGCs (Fig. 6C). A reduction 
of adenylate cyclase activity, produced either indirectly by brimonidine via α2 receptor 
activation (Fig. 6D) or directly by SQ222536 (Fig. 6A & 6E), can lead to the same effect: 
suppression of NMDA receptor function likely through a decrease in intracellular cAMP 
concentration. On the other hand, forskolin blocks brimonidine’s effect likely through 
neutralizing brimonidine’s effect on adenylate cyclase activity and therefore preventing 
significant alteration of intracellular cAMP concentration (Fig. 6B & 6F). 
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Fig. 4. Activation and intracellular signaling pathways of the α2 receptor 
 
 
Fig. 5. Brimonidine modulation of NMDA receptor function. See the text for details 
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Fig. 6. Effects of an adenylate cyclase (AC) inhibitor and activator. See the text for details 
Results with other tool agents provide additional support that brimonidine’s effect is 
mediated by the Gαi pathway. To avoid potential global indirect effects of intracellularly 
acting tool agents on recorded RGCs, we applied those agents intracellularly through the 
recording pipette. Therefore, the effects are largely limited within the recorded RGCs. 
Intracellular application of Sp-cAMPS, a synthetic cell-permeable, hydrolysis-resistant 
cAMP analog, blocks completely brimonidine’s effect on NMDA receptor function (Fig. 7A). 
To confirm that the lack of brimonidine’s effect is indeed due to the presence of intracellular 
Sp-cAMPS, but not because of damage caused by patch-clamping, we recorded the same 
group of RGCs twice: in the presence and absence of Sp-cAMPS. After the first set of 
recordings were done with the electrode attached (Fig. 7A), we successfully removed the  
Sp-cAMPS-filled recording electrodes from 5 RGCs without causing significant damage to 
those cells. After waiting for a few minutes to allow the residual intracellular Sp-cAMPS to 
diffuse out of the RGCs and wash away, we observed a typical brimonidine-induced 
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suppression of NMDA induced Ca++ signal in the same group of RGCs (Fig. 7B, note: the 
Ca++ dye delivered intracellularly by the electrode is a membrane impermeable form of 
Fluo-4 and therefore stayed inside the RGCs even after the electrode was removed). Thus, 
“clamping” intracellular cAMP level experimentally with equivalent synthetic cAMP analog 
is able to eliminate completely brimonidine’s effect. 
 
 
Fig. 7. Brimonidine’s effect is blocked by intracellular application of a cAMP analog 
In another experiment, we attempted to maintain endogenous intracellular cAMP level in 
RGCs through blocking its active degradation by phosphodiesterases (PDE). When 
rolipram, a type 4 PDE (a cAMP specific PDE) inhibitor (Teixeira et al., 1997), was 
intracellularly delivered through the recording electrode into a RGC, brimonidine’s 
suppressive effect on the NMDA receptor mediated transmembrane current and cytosolic 
free Ca++ signal was also completely blocked (Fig. 8A). In this RGC, we succeeded not only 
in removing the rolipram-filled electrode but also in re-recording the same RGC with a 
second, rolipram-free electrode. This allowed both electrical and optical recordings being 
repeated in the absence of the PDE inhibitor and typical brimonidine’s effect on NMDA 
responses was observed (Fig. 8B). These results demonstrate that preserving endogenous 
cAMP level through blocking its active degradation by PDE is also able to completely 
eliminate brimonidine’s effect, confirming that brimonidine’s effect is mediated by the Gαi–
AC–cAMP pathway coupled to the α2 receptor. 
Fig. 9 summarizes the sites of action of various tool compounds used in our studies to 
dissect out the intracellular signaling pathway through which brimonidine modulates 
NMDA receptor function. Among the tool agents, SQ22536 mimics brimonidine’s effect by a 
direct inhibition of the adenylate cyclase. Those in red are all able to block brimonidine’s 
effect at the different sites along the Gαi mediated signaling pathway. With these tool agents, 
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we have demonstrated clearly that brimonidine can down modulate NMDA receptor 
function in RGCs and this brimonidine’s effect is mediated predominantly, if not 
exclusively, by the Gαi–AC–cAMP pathway coupled to the α2 receptor. 
 
 
Fig. 8. Brimonidine’s effect is blocked by intracellular application of a PDE-4 inhibitor 
 
 
Fig. 9. The sites of action of the tool agents used along the Gαi–AC–cAMP pathway 
6. Validation in in vivo models 
To test whether α2 receptor mediated modulation of NMDA receptor function in in situ 
RGCs contributes significantly to RGC protection by brimonidine in in vivo models, we 
evaluated in in vivo models two of the tool agents, atipamezole and rolipram (Fig. 9), that 
have a proven CNS bioavailability after systemic application. Only a minority of all tool 
agents that work well in in vitro models can be used in in vivo models for target validation or 
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proof of concept due to practical reasons such as systemic toxicity, bioavailability, and 
unfavorable pharmacokinetics. Atipamezole and rolipram have already been successfully 
used in many whole animal studies for other purposes and are therefore chosen for use in 
our in vivo validation experiments.  
6.1 Rat glaucoma model 
The first in vivo model we tested is a rat glaucoma model. In this rat model, elevated IOP 
(from approximately 15 to 32 mmHg) produced by laser photocoagulation of episclearal and 
limbal veins leads to approximately 30% RGC loss evaluated at 3 weeks following the laser 
treatment (WoldeMussie et al., 2001; Dong et al., 2008). We used subcutaneous osmotic 
pumps to deliver brimonidine alone or in combination with atipamezole or rolipram. 
Memantine, an NMDA receptor channel blocker, was also used as a positive control to 
confirm the role of the NMDA receptor in RGC injury in this experimental glaucoma model 
(WoldeMussie et al, 2002).  
 
 
Fig. 10. Brimonidine’s protection of RGCs in the rat glaucoma model is mediated by the Gαi–
AC–cAMP signaling pathway coupled to the α2 receptor. See the Dong et al., 2008 for 
technical details 
We used a computer-controlled automated microscope stage and counted dextran 
tetramethylrhodamine retrogradely labeled RGCs at 24 sites (Fig. 10A). Fig. 10B shows 
representative images from an intermediate retinal location taken from a normal rat and 
glaucomatous rats under various treatment conditions: laser treatment alone (COHT for 
chronic ocular hypertension), COHT treated with memantine (COHT+mem), brimonidine 
(COHT+brim), brimonidine plus atipamezole (COHT+brim+atip), brimonidine plus 
rolipram (COHT+brim+rolip). Both memantine and brimonidine provided substantial 
protection of RGCs in this rat glaucoma model (Fig. 10C), consistent with the observations 
reported in previous studies (WoldeMussie et al., 2001, 2002). We found that brimonidine’s 
protective effect was completely blocked by co-administration of atipamezole, verifying for 
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the first time that brimonidine’s effect is indeed mediated by the α2 receptor. Furthermore, 
RGC protection by brimonidine was also completely blocked by co-administration of 
rolipram, a novel finding that identifies PDE-4 as a key endogenous player contributing to 
brimonidine’s protection of RGCs. Together these in vivo results suggest strongly that the 
Gαi–AC–cAMP signaling pathway coupled to the α2 receptor, described above in in situ 
RGCs, is responsible for RGC protection by brimonidine in this rat glaucoma model.  
6.2 Rabbit retinal NMDA model 
In animal glaucoma models, ranging from mouse to monkey (including the rat model used 
here), NMDA receptor mediated excitotoxicity is a major contributor to RGC injury 
regardless whether IOP elevation is produced biophysically (Dong et al., 2008; Hare et al., 
2004; WoldeMussie et al., 2002) or genetically (Ju et al., 2009). We have demonstrated that 
brimonidine down-modulates NMDA receptor function through the α2 receptor coupled 
Gαi–AC–cAMP signaling pathway (see Fig. 4 and Fig. 9 above). We also showed that the 
same Gαi pathway is responsible for brimonidine’s protection of RGCs in the rat glaucoma 
model (Fig. 10). Therefore, it is likely that brimonidine protects RGCs in the glaucoma 
models, at least in part, through attenuation of NMDA receptor mediated excitotoxicity.  
 
 
Fig. 11. Brimonidine’s protection of RGCs in the rabbit retinal NMDA model is mediated by 
the Gαi–AC–cAMP signaling pathway coupled to the α2 receptor. See the text for details 
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To test this directly, we used the rabbit retinal NMDA excitotoxicity model described in 
section 3 above (Fig. 3). We counted the total number of all neurons in the ganglion cell 
layer at 25 sites (Fig. 11A) at 2 weeks following intravitreal application of NMDA alone or in 
combination with other tool agents (Fig. 11D). These tool agents were applied intravitreally 
3 times: 1 hour prior to NMDA injection, co-injected with NMDA, and 24 hours following 
NMDA injection (See Dong et al., 2008 for details). In the rabbit retinal ganglion cell layer, 
approximately two-thirds of the neurons are RGCs and the remaining one-third are 
displaced amacrine cells, predominantly displaced starburst amacrine cells (dsACs, 85% of 
all displace amacrine cells, Vaney, 1984; Vaney et al., 1981). These dsACs can be selectively 
labeled with a very low dose of DAPI (4',6-diamidino-2-phenylindole, a fluorescent nuclear 
dye, Vaney et al., 1981; Dong et al., 2010). We found that these dsACs are resistant to NMDA 
excitotoxicity: the same intravitreal dose of NMDA (3.6 μmol) that produced a substantial 
cell loss at ganglion cell layer had no effect on dsACs (Fig. 11C), indicating a selective 
vulnerability of RGCs to NMDA receptor mediated excitotoxicity. 
RGC loss produced by intravitreal injection of NMDA is caused by excessive activation of 
NMDA receptors on RGCs since it can be completely blocked by MK801 (Fig. 11D), a potent 
and selective NMDA receptor channel blocker (Thompson et al., 1990). RGC loss can also be 
significantly attenuated by memantine (a less potent, but safer NMDA channel blocker, Fig. 
11D). Pretreatment with brimonidine produced a significant protection of RGCs against 
NMDA excitotoxicity. This protective effect was completely blocked by co-pretreatment 
with the α2 receptor antagonist atipamezole (Fig. 11D), verifying that brimonidine’s 
protection of RGCs against NMDA excitotoxicity is mediated by the α2 receptor. The PDE-4 
inhibitor, rolipram, also blocked brimonidine’s effect in a dose-dependent manner at 12 and 
120 nmol (Fig. 11D), indicating that this effect is mediated by the Gαi–AC–cAMP signaling 
pathway coupled to the α2 receptor (Fig. 4). 
 
 
Fig. 12. Brimonidine modulation of L-type Ca++ channel function at IPL. See the text for 
details 
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We have shown with in situ RGCs that brimonidine modulates NMDA receptor function 
through the α2 receptor coupled Gαi–AC–cAMP signaling pathway (Dong et al, 2008; see 
section 5 above). We have also shown that brimonidine protects RGCs through the same 
Gαi–AC–cAMP signaling pathway in both experimental glaucoma and retinal NMDA 
excitotoxicity models (Figs. 10 and 11). Together, our ex vivo and in vivo data suggest 
strongly that brimonidine modulation of NMDA receptor function is a major mechanism of 
RGC protection in experimental glaucoma. 
7. Modulation of retinal L-type Ca++ channel function by brimonidine at IPL 
In addition to modulation of NMDA receptor function postsynaptically in RGCs, 
brimonidine was also found to modulate the function of voltage-gated Ca++ channel at IPL 
(Dong et al., 2007), a major retinal synaptic layer where communication between RGCs and 
their presynaptic partners, such as bipolar cells, takes place. In the most regions of CNS, 
release of neurotransmitters are mediated by voltage-gated N- and P/Q types of Ca++ 
channels (Reid et al., 2003). However, in the retina the L-type Ca++ channel plays a dominant 
role in transmitter release, particularly at photoreceptor and bipolar cell synaptic terminals 
where glutamate is released (Morgans et al., 2005; Pan, 2000, 2001; Tachibana et al., 1993).  
Using several commonly used L-type Ca++ channel blockers, we demonstrated that the 
depolarization (using a high K+ Ringer) induced Ca++ signals at IPL were mediated 
predominantly by the L-type Ca++ channel (Dong et al., 2010; see also Fig. 12B & 12C). We 
also showed that brimonidine down modulated this L-type channel mediated Ca++ signal 
(Dong et al., 2007; see also Fig. 12D). Brimonidine’s effect was blocked by Sp-cAMPS, 
forskolin, and yohimbine (a selective α2 antagonist), indicating that the effect is also 
mediated by the α2 receptor coupled Gαi–AC–cAMP signaling pathway (Fig. 12E). 
A major contributor to the depolarization induced Ca++ signal at IPL is the presynaptic 
terminals of bipolar cells (Fig. 1C & 1D) where L-type Ca++ channels are expressed in high 
density for glutamate release (Pan, 2000, 2001; Tachibana et al., 1993). We found at the 
presynaptic terminals from individual in situ bipolar cells (Fig. 1C) that the Ca++ signal 
induced by a depolarization voltage step applied through a patch-clamp electrode (Fig. 1D) 
was also modulated by brimonidine (unpublished observation). Thus, together our results 
suggest that preventing presynaptic glutamate overrelease by brimonidine is likely an 
additional neural mechanism contributing to brimonidine’s protection of RGCs in 
experimental glaucoma and acute retinal ischemia. It is also consistent with the observation 
that brimonidine application reduced vitreal glutamate concentration in acute retinal 
ischemia (Donello et al., 2001). 
8. Other neuroprotective effects by brimonidine 
In addition to preventing RGC Ca++ overload by modulating activities of both voltage-gated 
(Fig. 12) and ligand-gated (Fig. 5) Ca++ channels that are pre- and post-synaptic to RGCs, 
brimonidine can also up-regulate survival factors/pathways in the retina. For example, in 
acute retinal ischemia, brimonidine’s neuroprotection is associated with up-regulation of 
basic fibroblast growth factor, bcl-2, bcl-xl, as well as activation of the PI3 kinase/protein 
kinase B (Akt) and extracellular-signal-regulated kinase (ERK) pathways (Lai et al., 2002). 
We believe that some of these beneficial effects of brimonidine may be related to its 
modulation of NMDA receptor function (Fig. 5). For example, increased expression of bcl-2 
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and decrease expression of Bax (a proapoptosis member in the bcl-2 family) is associated 
with blockage of the NMDA receptor by memantine in a mouse glaucoma model (DBA/2J, 
Ju et al., 2009). 
In experimental glaucoma (Lambert et al., 2011) and acute retinal ischemia (López-Herrera 
et al., 2002), brimonidine also preserves retrograde and anterograde axonal transport in 
RGCs. This brimonidine’s effect may be related to its action on preventing intracellular Ca++ 
overload in RGCs via modulation of NMDA receptor function (Fig. 5), since a healthy soma 
and unimpaired mitochondrial function are required to provide energy needed for effective 
transport. It is well established that mitochondria dysfunction caused by NMDA receptor 
mediated Ca++ overload plays a central role in neuronal cell death in disease states 
(Pivovarova & Andrews, 2010; Stout et al., 1998). Indeed, in experimental glaucoma, it has 
been shown recently that RGC injury is associated with NMDA receptor mediated 
mitochondrial dysfunction and can be prevented by NMDA receptor blockade with 
memantine (Ju et al., 2009).  
9. Conclusion 
Neuronal Ca++ dysregulation, particularly Ca++ overload caused by excessive activation of 
the NMDA receptor and voltage-gated Ca++ channels, is an important common final 
pathway leading to neural dysfunction/death in a wide range of CNS neurodegenerative 
diseases (Bezprozvanny, 2009).  
Our ex vivo and in vivo findings have provided strong evidence that functional modulation 
of the NMDA receptor (Fig. 4) and the L-type Ca++ channel (Fig. 12) in the retina are two key 
mechanisms through which brimonidine protects RGCs in animal models of glaucoma and 
retinal excitotoxicity. Brimonidine also upregulates pro-survival molecules and pathways 
(Lai et al., 2002). These mechanisms may contribute to brimonidine’s IOP-independent 
preservation of visual function in human glaucoma (also a CNS neurodegenerative disease) 
observed in a recent randomized, double-masked, multicenter clinical trial (Krupin at al., 
2011).    
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